ArticlePsychopharmacology2026
The effects of low-dose ketamine and (2R,6R)-Hydroxynorketamine on affective behaviors associated with protracted oxycodone withdrawal.
Article in Psychopharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
rationaleIn subjects with opioid use disorder (OUD), affective symptoms persist long after opioid cessation and contribute to poor treatment outcomes. (2R,6R)-Hydroxynorketamine (HNK), a ketamine metabolite, has emerged as promising rapid-acting and long-lasting antidepressants, but its potential to reduce affective symptoms during protracted oxycodone withdrawal and the mechanism of action remain unclear.
objectiveThe objective of this study is to investigate the effects of (2R,6R)-HNK and ketamine on affective-like behaviors during oxycodone withdrawal and evaluate the underlying mechanism.
methodsMale and female C57BL/6 N mice were injected with saline or escalating dose of oxycodone for eight consecutive days followed by 30 days of protracted withdrawal. On withdrawal day 1 or 29, mice were treated with saline, (2R,6R)-HNK (10 mg/kg), s.c.), or ketamine (10 mg/kg, s.c.) prior to the social interaction, sucrose preference, or tail suspension test on withdrawal day 30. Additionally, to determine if AMPA receptor signaling was necessary for the treatment effect, NBQX (AMPA receptor antagonist) was administered prior to (2R,6R)-HNK or ketamine in a different cohort of mice.
resultsBoth (2R,6R)-HNK and ketamine reversed oxycodone-induced deficits to a similar degree in all behavior tests when administered on withdrawal day 1, and pre-treatment with NBQX attenuated this effect in the tail suspension test but not the social interaction or sucrose preference tests. When ketamine or (2R,6R)-HNK was administered on withdrawal day 29, both treatments alleviated deficits in the tail suspension test but lacked effects in other behaviors.
conclusionsThese findings demonstrate the therapeutic potential of (2R,6R)-HNK and ketamine in alleviating affective symptoms of oxycodone withdrawal.
Indexed as
Identifiers
41045335What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.